JUND and neoplasm: Only one study [19] on the GTE cohort showed that survival rate of mutated MEN1 patients was significantly lower among carriers of a MEN1 mutation affecting binding sites with JunD, presenting a 2-fold higher death risk of MEN1-associated tumours; no association was found between mutations and other peculiar phenotypic features.